Selective targeting of BCL2 with venetoclax had a manageable safety profile and induces substantial responses in patients with relapsed CLL or Small Lymphocytic Lymphoma, including those with poor prognostic features31. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.